Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides

Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides

US Patent 12221459 · Granted Feb 11, 2025

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Base-modified cytidine nucleotides for leukemia therapy2025
Dioxolane analogues of uridine for the treatment of cancer2022
Dioxolane analogues of uridine for the treatment of cancer2022
Sorafenib or regorafenib troxacitabine phosphoramidate prodrug combination thera2021
Sorafenib or regorafenib troxacitabine phosphoramidate prodrug combination thera2021
Dioxolane analogues of uridine for the treatment of cancer2020
Dioxolane analogues of uridine for the treatment of cancer2020
Dioxolane analogues of uridine for the treatment of cancer2020
Dioxolane analogues of uridine for the treatment of cancer2020
Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug 2019
Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug 2019
Dioxolane analogues of uridine for the treatment of cancer2019